Scarica l'app Stockscreener
0.9725
1.30%
0.0125
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ADIL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.96
Aprire:
$1.02
Volume 24 ore:
96,637
Relative Volume:
0.56
Capitalizzazione di mercato:
$6.30M
Reddito:
-
Utile/perdita netta:
$-6.07M
Rapporto P/E:
-0.1683
EPS:
-5.78
Flusso di cassa netto:
$-7.34M
1 W Prestazione:
-4.66%
1M Prestazione:
-9.11%
6M Prestazione:
-10.78%
1 anno Prestazione:
-23.73%
Intervallo 1D:
$0.9617
$1.02
Intervallo di 1 settimana:
$0.96
$1.0583
Portata 52W:
$0.765
$4.1699
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Nome
Adial Pharmaceuticals Inc
Settore
Industria
Telefono
434-422-9800
Indirizzo
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Confronta ADIL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
0.9725 | 6.30M | 0 | -6.07M | -7.34M | -5.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
| 2018-10-30 | Iniziato | Maxim Group | Buy |
| 2018-10-11 | Iniziato | Dawson James | Buy |
Adial Pharmaceuticals Inc Borsa (ADIL) Ultime notizie
Why Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars Today - MSN
Adial Pharmaceuticals to Commence Business Development Meetings - Defense World
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
Adial Pharmaceuticals Focuses on Strategic Growth Initiatives - TipRanks
Adial Pharmaceuticals Highlights AD04 for Alcohol Use Disorder - TipRanks
Alcohol Use Disorder Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight - Barchart
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Up 16.4% in December - Defense World
Adial Pharmaceuticals (NASDAQ:ADIL) Stock Quotes, Forecast and News Summary - Benzinga
Adial Pharmaceuticals’ New Purchase Agreement with Alumni Capital - TipRanks
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Drops By 71.7% - Defense World
Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Adial Pharmaceuticals revises CEO's compensation package By Investing.com - Investing.com South Africa
Adial Pharmaceuticals revises CEO's compensation package - Investing.com India
Adial Pharmaceuticals secures new patent for AUD therapy By Investing.com - Investing.com South Africa
EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations - AOL
Adial Pharmaceuticals, Inc. Updates on Onward Phase 3 Pivotal Trial - Marketscreener.com
Adial Pharmaceuticals secures new patent for AUD therapy - Investing.com
Adial Pharmaceuticals Granted Key U.S. Patent for the - GlobeNewswire
Adial Pharmaceuticals Secures Key Patent for Alcohol Use Disorder Treatment Technology - StockTitan
Alcohol Use Disorder Treatment Market Report Analysis - openPR
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Large Growth in Short Interest - Defense World
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know - MSN
Equities Analysts Offer Predictions for ADIL FY2024 Earnings - Defense World
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Adial Pharmaceuticals (NASDAQ:ADIL) Coverage Initiated at Rodman & Renshaw - Defense World
RODMAN&RENSHAW Upgrades Adial Pharmaceuticals (NASDAQ:ADIL) to “Strong-Buy” - Defense World
ARMISTICE CAPITAL, LLC Acquires New Stake in Adial Pharmaceutica - GuruFocus.com
Rodman & Renshaw sets stock target, buy rating on Adial Pharma, cites potential - Investing.com India
U.S. STOCKS Oklo, Adial Pharma, Sonos - XM
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder - AOL
Adial Pharmaceuticals completes key study for FDA meeting - Investing.com
Adial Pharmaceuticals Announces Positive Topline Results - GlobeNewswire
Adial Pharma's AD04 Drug Hits Key Milestones in Alcohol Use Disorder Treatment Study | ADIL Stock News - StockTitan
This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Adial Pharma Reports Mixed Q3: AUD Drug Study Advances Despite Widening Losses | ADIL Stock News - StockTitan
Adial Pharmaceuticals Approves Strategic Changes at Annual Meeting - TipRanks
Adial Pharmaceuticals Appoints Vinay Shah as CFO - Defense World
Adial Pharmaceuticals names new CFO amid strategic growth By Investing.com - Investing.com Australia
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - GlobeNewswire
Adial Pharmaceuticals names new CFO amid strategic growth - Investing.com
Adial Pharma Taps Veteran CFO with $150M+ Fundraising Track Record | Key Executive Move | ADIL Stock News - StockTitan
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference - The Manila Times
EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate - AOL
Adial Pharmaceuticals patent expands for alcohol disorder drug - Investing.com
Adial Pharmaceuticals patent expands for alcohol disorder drug By Investing.com - Investing.com Canada
Adial Pharmaceuticals Receives Notice of Allowance for U.S. - GlobeNewswire
Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment - Yahoo Finance
Adial Pharmaceuticals Inc Azioni (ADIL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):